| domain | takeda.com |
| summary | Takeda Pharmaceuticals is a global company focusing on various areas such as Gastrointestinal and Inflammation, Rare Diseases, Plasma-Derived Therapies, Oncology, Neuroscience, and Vaccines. The company presents its financial results for FY2025 Q2 in November 2025, highlighting the sustained effect of Mezagitamab TAK-079 on kidney function after treatment in Primary IgA Nephropathy. Additionally, they released new Phase 3 data showing that their Dengue vaccine delivers seven years of sustained protection against infection and hospitalization. Investors can sign up for a newsletter to stay updated on financial results, corporate milestones, and learn how Takeda is committed to patients, employees, and the planet. |
| title | Takeda Pharmaceuticals: Global Homepage |
| description | Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future. |
| keywords | english, spanish, diseases, french, more, patients, results, health, sustainability, disclosures, governance, science, investors, german, russian, chinese, arabic |
| upstreams |
|
| downstreams |
|
| nslookup | A 13.248.133.121, A 76.223.3.151 |
| created | 2025-11-10 |
| updated | 2025-11-25 |
| summarized | 2025-11-26 |
|
|